ArticleFrontiers in oncology2026
Integration of network toxicology and transcriptomics reveals the potential regulatory role of the 'Arecoline/4-NQO-AKT1-m6A factor' axis in the development of OSCC.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The synergistic carcinogenic effect of areca nut chewing and tobacco exposure is a major risk factor for oral squamous cell carcinoma (OSCC). However, the molecular mechanisms, particularly related to N6-methyladenosine (m6A) modification, remain unclear. This study explores the potential mechanisms by which arecoline and 4-nitroquinoline-1-oxide (4-NQO) induce OSCC, focusing on m6A regulatory factors and key targets. Methods: Transcriptional data were obtained from Gene Expression Omnibus (GEO), with differentially expressed genes (DEGs) identified using the limma package. The intersection of DEGs and 21 m6A regulators was analyzed, and their prognostic relevance was validated with The Cancer Genome Atlas (TCGA) data. Arecoline and 4-NQO targets were identified through online databases, and compound-target and protein-protein interaction (PPI) networks were constructed. Core targets were selected using Degree, MCC, and FRIENDS algorithms. Spearman analysis assessed correlations with m6A factors, and molecular docking was performed to verify binding properties. Results: Heterogeneous Nuclear Ribonucleoprotein C (HNRNPC), AlkB Homolog 5 (ALKBH5), and ELAV Like RNA Binding Protein 1 (ELAVL1) were identified as key genes. High HNRNPC expression correlated with poor prognosis. AKT Serine/Threonine Kinase 1 (AKT1) was the core target across algorithms, with significant correlations between AKT1 and m6A factors. Molecular docking indicated potential binding between AKT1 and the compounds. Conclusion: This study establishes a regulatory network linking arecoline/4-NQO, AKT1, m6A factors, and OSCC, and identifies key molecular targets and mechanisms underlying the carcinogenic process. These findings provide a theoretical foundation for understanding the pathogenesis of OSCC and developing targeted strategies for early intervention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.